Table 1. Demographic and clinical description of study participants with a pre-TVUS epithelial cell maturity index (MI) less than or more than 3.
| Characteristic | MI < 3 | MI > 3 | p-value |
|---|---|---|---|
| N Median | N Median | ||
| (%) (Q1-Q3) | (%) (Q1-Q3) | ||
| Age (years) | 31 (27–51) | 35 (31–40) | 0.82c |
| Menopausal status | 0.05a | ||
| Pre-menopausal | 12 (67%) | 29 (91%) | |
| Peri/post-menopausal | 6 (33%) | 3 (9%) | |
| Race | 0.69a | ||
| Black or African American | 12 (67%) | 22 (69%) | |
| White | 4 (22%) | 6 (19%) | |
| Asian | 2 (11%) | 1 (3.1%) | |
| Multiracial | 0 (0.0%) | 2 (6.3%) | |
| Other | 0 (0.0%) | 1 (3.1%) | |
| Current use of hormonal contraception | 5 (29%) | 13 (42%) | 0.65b |
| Type of hormonal contraception | |||
| Oral contraceptive | 2 (11%) | 4 (13%) | |
| IUD (progestin) | 2 (11%) | 4 (13%) | |
| Implant | 1 (6%) | 5 (16%) | |
| Menses reported on day of TVUS | 3 (17%) | 4 (13%) | 0.70a |
| TVUS Indications | |||
| Assessment of pelvic mass | 6 (33%) | 11 (34%) | 0.94b |
| Localization of intrauterine device | 2 (11%) | 3 (9.4%) | 0.99a |
| Abnormal uterine bleeding | 1 (5.6%) | 10 (31%) | 0.07a |
| Screening for malignancy | 0 (0.0%) | 1 (3.1%) | 0.99a |
| Pelvic pain | 10 (56%) | 11 (34%) | 0.14b |
| Other | 3 (17%) | 1 (3.1%) | 0.13a |
| TVUS Findings | |||
| Adenomyosis | 0 (0.0%) | 3 (9.4%) | 0.54a |
| Fibroids | 4 (22%) | 9 (28%) | 0.75a |
| Cysts | 1 (5.6%) | 5 (16%) | 0.40a |
| Other | 4 (22%) | 8 (25%) | 0.99a |
| No significant findings | 11 (61%) | 8 (25%) | 0.01b |
The median weight of CVF recovered by clinician collection at W1-post-TVUS was 86 mg (IQR 28–172 mg); the median weight recovered by participant self-collection at W2-post-TVUS was 62 mg (IQR 9–176 mg). There was no significant difference in weight comparing paired clinician-collected and participant-collected samples at W1-post-TVUS and W2-post-TVUS, respectively, p = 0.81.
Differences across groups assessed by Fisher’s exact test (a), chi-square test (b), and Wilcoxon rank sum test (c).